Ticker: EXEL

Exelixis shares slide over 9% following mixed results from late-stage trials for colorectal and neuroendocrine tumors, highlighting challenging paths in oncology drug development.

Exelixis, Inc. (NASDAQ: EXEL) has reported its quarterly financial results for the period ending June 30, 2025. The following key points and statistics summarize the company's current financial status and significant developments. Revenues: Total revenues: $568.3 million, down 11% from $637.2 m...